|
|
|
Home >
Health Conditions > Breast Cancer >
Femara.
Femara (letrozole) - 1/01
Related Topics:
Where to purchase:
For
Aromatization (in males):
-
Comparative Assessment in Young and Elderly Men of the Gonadotropin Response
to Aromatase Inhibition - JCEM, 1/10/05 - "In
both the young and elderly group, SHBG levels decreased during letrozole
treatment (P = 0.003 and <0.001, respectively; P value for young vs. elderly
was not significant). The ratios T/E2 and FT/FE2 were significantly higher
after letrozole treatment in both groups" - See
letrozole at inhousepharmacy.vu.
- Effects of
transdermal testosterone gel or an aromatase inhibitor on serum
concentration and pulsatility of growth hormone in older men with
age-related low testosterone - Metabolism. 2017 Apr;69:143-147 -
"Thirty-seven men, ≥65years with total testosterone
<350ng/dL were randomized to 5g transdermal testosterone gel (TT), 1mg oral
aromatase inhibitor (AI) or placebo daily for 12months ... At 6months, IGF-1
significantly increased by Δ 15.3±10.3ng/ml in the TT-group compared to
placebo (P=0.03). Both intervention groups significantly increased GH pulse
frequency (TT-group, P=0.04; AI-group, P=0.05) compared to placebo. The GH
secretory-burst mode (duration) significantly decreased in the TT-group
(P=0.0018) compared to placebo while it remained unchanged in the AI-group"
- Note: Everything I've read over the years seems to indicate that low
dose Femara is a better way to go than testosterone replacement (which
increases estrogen as much as testosterone percentage wise).
-
Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on
Prostate Volume in older men - J Clin Endocrinol Metab. 2016 Mar 7 -
"Randomization to 5 g transdermal testosterone gel
(TT), 1 mg oral aromatase inhibitor (AI) or placebo daily for 12 months ...
lower urinary tract symptoms (LUTS) score ... Serum testosterone levels
increased in both intervention groups; estradiol levels increased in the
TT-group while it decreased in the AI-group. At 12 months, prostate volume
significantly increased (4.5±1.76 cc, p<0.05) only in the TT group. Increase
in PSA levels were seen in both intervention groups at 6 months (p<0.01 and
p<0.001). LUTS score increased only in the TT group (p<0.05)"
-
Restoring testosterone rather than replacing it helps safeguard a man's
fertility - Science Daily, 10/27/15 - "One of
the basic tenets in medicine is to do no harm. As this study has shown in a
randomized, double-blind, double-dummy, placebo-controlled manner, exogenous
testosterone therapy with Androgel can clearly decrease sperm production and
potentially impact fertility ... This study confirmed that Enclomiphene can
maintain spermatogenesis while restoring testosterone levels to normal"
- Note: It just seems like Femara (letrozole) is a better way to go
but I'm not a doctor.
-
Letrozole is a promising new treatment of male infertility - Science
Daily, 3/7/14 - "Some recently published studies
have suggested that in men with obesity-related low testosterone, a low dose
of letrozole can normalize testosterone levels ... Doctors think obesity can
cause infertility in men because excess fat results in too much estrogen.
The body's aromatase enzyme, which is more prevalent in fat, converts
androgens (male hormones, such as testosterone) into estrogen. Letrozole
inhibits this action of aromatase ... The men received a 2.5-milligram
letrozole pill every week"
-
Successful use of aromatase inhibitor letrozole in NOA with an elevated FSH
level: a case report - Andrologia. 2013 Jun 26 -
"We present the case of an infertile man with small testes and an elevated
FSH level, which was diagnosed as NOA, hypospermatogenesis proven by
testicular biopsy. After taking letrozole for 3 months, semen analyses by
computer-aided sperm analysis present that this man had normal
spermatogenesis"
-
Drugs for hair loss and benign prostatic hyperplasia may result in loss of
libido, erectile dysfunction in men - Science Daily, 1/11/11 -
"5a-reductase inhibitors (5a-RIs), while improving
urinary symptoms in patients with benign prostatic hyperplasia (BPH) and
possible hair loss prevention, produces significant adverse effects in some
individuals including loss of libido, erectile dysfunction (ED), ejaculatory
dysfunction and potential depression" - Note: That goes back and
forth. One study claimed that finasteride improved sex after after six
months of taking it. Regarding gynaecomastia, if you're taking low dose
letrozole to increase testosterone and to prevent aromatization it may also
help prevent gynaecomastia.
-
Prostate Drug May Not Dim Sex - WebMD, 6/26/07 -
"Six months after the men started taking their assigned drugs, the
survey scores were about three points higher for the men taking Proscar.
By the end of the study, that gap narrowed to about two points"
-
Prostate Drug Doesn't Limit Sexual Function In Most Men - Science Daily,
7/19/07 - "The study suggests that finasteride will
cause little or no sexual dysfunction for most men who decide to take it"
-
Ask a Medical Question - Can letrozole cure gynecomastia - JustAnswer
-
"Letrozole may be effective in preventing and
reversing the gynaecomastia provided it is used early enough in steroid
induced gynaecomastia" - I
believe the recommended dose is something like a quarter tablet every
three days but don't quote me on it. That's what I take.
-
Aromatase Inhibition Offers Little Benefit, Possible Harm to Men With Lo...
- Medscape, 12/22/09 - "The inescapable conclusion from
these data is that the 50% increase in testosterone levels was trumped by the
much more modest 20% reduction in estradiol levels, leading to negative skeletal
effects of anastrozole therapy in aging men" - Note: I'm not sure
that thought this though thoroughly. Mortally in men is best when estrogen
is around 25pg/mL. I suspect that most have higher estrogen than that.
See:
-
High, Low Estradiol Levels and Mortality in Men With Systolic HF -
Medscape, 5/19/09 - "Both low and high serum levels
of estradiol, compared with mid-range levels, are significantly and
independently associated with increased all-cause mortality in men with
chronic systolic heart failure"
Serum Estradiol Concentration Quintiles as Predictors of All-Cause Mortality
in Men (With Quintile 3 as the Reference Group)
| Parameter |
Quintile 1 |
Quintile 2 |
Quintile 3 |
Quintile 4 |
Quintile 5 |
| Estradiol concentration (pg/mL) |
<12.903 |
12.90–21.79 |
21.80–30.11 |
30.12–37.39 |
>37.40 |
| 3-y survival* (%) |
44.6 |
65.8 |
82.4 |
79.0 |
63.6 |
| Quintile as mortality predictor,* HR (95% CI) vs quintile 3 |
4.17 (2.33–7.45) |
2.15 (1.16–3.99) |
-- |
1.22 (0.64–2.31) |
2.33 (1.30–4.18) |
HR= hazard ratio
-
High, Low Estradiol Levels and Mortality in Men With Systolic HF -
Medscape, 5/19/09 - "Both low and high serum levels
of estradiol, compared with mid-range levels, are significantly and
independently associated with increased all-cause mortality in men with
chronic systolic heart failure"
- Note: See my aromatization page
for ways to reduce it. I take a quarter tablet of letrozole every day.
-
- Serum Estradiol Concentration Quintiles as Predictors
of All-Cause Mortality in Men (With Quintile 3 as the Reference Group)
| Parameter |
Quintile 1 |
Quintile 2 |
Quintile 3 |
Quintile 4 |
Quintile 5 |
| Estradiol concentration (pg/mL) |
<12.903 |
12.90–21.79 |
21.80–30.11 |
30.12–37.39 |
>37.40 |
| 3-y survival* (%) |
44.6 |
65.8 |
82.4 |
79.0 |
63.6 |
| Quintile as mortality predictor,* HR (95% CI) vs quintile 3 |
4.17 (2.33–7.45) |
2.15 (1.16–3.99) |
-- |
1.22 (0.64–2.31) |
2.33 (1.30–4.18) |
HR= hazard ratio -
Obesity Linked To Hormone Imbalance That Impacts Sexual Quality Of Life
- Science Daily, 3/3/09 - "In our study population,
we found that lower testosterone levels and diminished ratings for sexual
quality of life were correlated with increased BMI ... Subjects who lost
weight through bariatric surgery experienced a reduction in estradiol
levels, an increase in testosterone levels and an increase in ratings of
sexual quality of life" - See my
aromatization page.
-
Short-term aromatase inhibition: effects on glucose metabolism and serum
leptin levels in young and elderly men - Eur J Endocrinol. 2008 Dec 2 -
"Ten elderly and nine young healthy men were
randomized to receive letrozole 2.5 mg daily or placebo for 28 days in a
crossover design. Results: Both in young and elderly men, active treatment
significantly increased serum testosterone (+128 and +99%, resp.) and
decreased estradiol levels (-41 and -62%, resp.). Fasting glucose and
insulin levels decreased in young men after active intervention (-7 and
-37%, resp.) compared to placebo. Leptin levels fell markedly in both age
groups (-24 and -25%, resp.), while adiponectin levels were not affected by
the intervention. Lipid profile was slightly impaired in both groups, with
increasing LDL-cholesterol levels (+14%) in the younger age group and 10%
lower levels of ApoA1 in the elderly. A decline in IGF-1 levels (-15%) was
observed in the younger age group. No changes in weight or BMI were observed
in either young or old men"
-
Letrozole once a week
normalizes serum testosterone in obesity-related male hypogonadism - Eur
J Endocrinol. 2008 May;158(5):741-7 -
"Isolated hypogonadotropic hypogonadism (IHH) is
frequently observed in severely obese men, probably as a result of increased
estradiol (E(2)) production and E(2)-mediated negative feedback on pituitary
LH secretion. Aromatase inhibitors can reverse this process ... treated with
2.5 mg letrozole once a week for 6 months ... Six weeks of treatment reduced
total E(2) from 123+/-11 to 58+/-7 pmol/l (P<0.001, mean+/-s.e.m.), and
increased serum LH from 4.4+/-0.6 to 11.1+/-1.5 U/l (P<0.001). Total
testosterone rose from 5.9+/-0.5 to 19.6+/-1.4 nmol/l (P<0.001), and free
testosterone from 163+/-13 to 604+/-50 pmol/l (P<0.001). Total testosterone
rose to within the normal range in all subjects, whereas free testosterone
rose to supraphysiological levels in 7 out of 12 men ... Letrozole 2.5 mg
once a week produced a sustained normalization of serum total testosterone
in obese men with IHH. However, free testosterone frequently rose to
supraphysiological levels. Therefore, a starting dose <2.5 mg once a week is
recommended"
-
Comparative Assessment in Young and Elderly Men of the Gonadotropin Response
to Aromatase Inhibition - JCEM, 1/10/05 - "In
both the young and elderly group, SHBG levels decreased during letrozole
treatment (P = 0.003 and <0.001, respectively; P value for young vs. elderly
was not significant). The ratios T/E2 and FT/FE2 were significantly higher
after letrozole treatment in both groups" - See
letrozole at inhousepharmacy.vu.
-
Comparative assessment in young and elderly men of the gonadotropin response
to aromatase inhibition - J Clin Endocrinol Metab. 2005
Oct;90(10):5717-22 - "As assessed after 28 d of
treatment, letrozole lowered E2 by 46% in the young men (P = 0.002) and 62%
in the elderly men (P < 0.001). In both age groups, letrozole, but not
placebo, significantly increased LH levels (339 and 323% in the young and
the elderly, respectively) and T (146 and 99%, respectively) (P value of
young vs. elderly was not significant). Under letrozole, peak LH response to
GnRH was 152 and 52% increase from baseline in young and older men,
respectively"
-
Letrozole normalizes serum testosterone in severely obese men with
hypogonadotropic hypogonadism - Diabetes Obes Metab. 2005 May;7(3):211-5
- "Six weeks of treatment decreased serum estradiol
from 120 +/- 20 to 70 +/- 9 pmol/l (p = 0.006). None of the subjects
developed an estradiol level of less than 40 pmol/l. LH increased from 4.5
+/- 0.8 to 14.8 +/- 2.3 U/l (p < 0.001). Total testosterone rose from 7.5
+/- 1.0 to 23.8 +/- 3.0 nmol/l (p < 0.001) without a concomitant change in
sex hormone-binding globulin level. Those treated with Letrozole 17.5 mg per
week had an excessive LH response" - Note: A half tablet per day
would be 8.75 mg/week. I believe 40 pmol/l of estradiol is
11.54
pg/mL and the normal value for men is
10 to 52 pg/mL (Quest
says
10 to 50). The way I read that, testosterone tripled.
-
Influence of letrozole
and anastrozole on total body aromatization and plasma estrogen levels in
postmenopausal breast cancer patients evaluated in a randomized, cross-over
study - J Clin Oncol. 2002 Feb 1;20(3):751-7 -
"estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) ... Treatment
with anastrozole suppressed plasma levels of E(1), E(2), and E(1)S by a mean
of 81.0%, 84.9%, and 93.5%, respectively, whereas treatment with letrozole
caused a corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The
suppression of E(1) and E(1)S was found to be significantly better during
treatment with letrozole compared with anastrozole"
-
Open dose-finding study of a new potent and selective nonsteroidal aromatase
inhibitor, CGS 20 267, in healthy male subjects
- J Clin Endocrinol Metab. 1993 Aug;77(2):319-23 -
"A reduction in estradiol levels by about 30% from baseline was observed at
the lowest dose (0.02 mg)" - CGS 20 267 is Letrozole.
-
Letrozole-Femara - isteroids.com -
"Letrozole is probably the most powerful Aromatase
Inhibitor used by athletes today"
-
Femara (Letrozole)
clinical pharmacology - RxList.com - "Letrozole's terminal elimination
half-life is about 2 days and steady-state plasma concentration after daily
2.5 mg dosing is reached in 2-6 weeks"
News & Research:
-
Vitamin D Counters Bone
Density Loss With Aromatase Inhibitors - Medscape, 12/14/21 -
"The researchers examined women before the start of
treatment, at 6 months, and at 5 years. Those with vitamin D levels below 30 ng/mL
received 7,000 IU/day for 8 weeks, followed by a 1,000 IU/day maintenance dose.
Subjects with osteopenia received a calcium supplement (500 mg calcium
carbonate), and those with osteoporosis received 4 mg zoledronic acid ...
Another prospective observational study, published earlier this year, looked at
vitamin D supplementation in 741 patients (mean age 61.9 years) being treated
with aromatase inhibitors, whose baseline vitamin D levels were less 30 ng/mL.
They received 16,000 IU dose of oral calcifediol every 2 weeks. At 3 months,
individuals who achieved vitamin D levels of 40 ng/mL or higher were less likely
to have joint pain (P < .05). At 12 months, data from 473 patients showed that
for every 10-ng/mL increase in serum vitamin D at 3 months, there was a
reduction in loss of bone marrow density in the lumbar spine (adjusted beta =
+0.177%, P < .05), though there were no associations between vitamin D levels
and BMD of the femur or total hip ... Our results suggest that optimal levels of
vitamin D are associated with a reduced risk of joint pain related to AI
treatment. A target threshold (of vitamin D) levels was set at 40 ng/mL to
significantly reduce the increase in joint pain." The authors noted that this
threshold is well above the goal of 20 ng/mL recommended by the 2010 Institute
of Medicine report" - See vitamin D at Amazon.com.
-
Vitamin D May Help
Breast Cancer Survivors Stay on Track - Medscape, 6/25/12 -
"women taking 30,000 IU of oral vitamin D3 weekly on
starting letrozole therapy achieved significant benefits in terms of
fatigue, joint pain, and disability from joint pain ... Aromatase inhibitors
are one of the most important endocrine treatments for breast cancer, but
the problem is that about half of the women have severe musculoskeletal pain
from these agents, and 18% to 30% report fatigue, [resulting in] a
discontinuation rate of about 10% each year ... pain relievers are the only
available treatment option ... Using the Simple Descriptive Pain Intensity
scale for analysis, only 37% of women receiving vitamin D3 supplementation
reported a musculoskeletal event (joint pain, disability from joint pain, or
resulting discontinuation of letrozole) at 6 months compared with 51% of
those in the placebo group ... In addition, significantly fewer patients
receiving vitamin D3 supplementation reported adverse quality of life
events, including worsening of pain, disability, or fatigue (42% vs 72%; P <
.001)" - See
vitamin D at Amazon.com
 .
-
Joint Supplements for
Aromatase Inhibitor Adverse Effects - Medscape, 11/18/11 -
"Aromatase inhibitors are widely used in the
treatment of breast cancer but are associated with significant
musculoskeletal adverse effects, including joint pain and stiffness ... We
know that these symptoms are unresponsive to conventional pain medication
and often lead to low adherence to aromatase inhibitor therapy ... The
cohort consisted of postmenopausal breast cancer patents with stage I to III
disease who had been on aromatase therapy for at least 3 months, who
reported a pain rating of 4 or higher on a 10-point visual analog scale, and
whose pain worsened after initiating treatment with aromatase inhibitors if
they had preexisting osteoarthritis ... Participants took 1500 mg/day of
glucosamine and 1200 mg/day of chondroitin, and were evaluated every 6 weeks
at the clinic ... There was a drop in pain and stiffness in the hips and
knees at 12 and 24 weeks, as well as improvement in function. "This affected
about 50% of the women," she explained. "We saw a very similar pattern
looking at the hands and the wrist. We saw similar results with the Brief
Pain/Stiffness Inventory — with about 35% to 50% of women."" - See
glucosamine products at Amazon.com
and
chondroitin sulfate at Amazon.com.
-
Breast Cancer Survival: Femara Better Than Tamoxifen - WebMD, 10/21/11 -
"At an average follow-up of more than eight years,
postmenopausal women who took Femara for five years after surgery were 20%
less likely to have their breast cancer return and 21% less likely to die
from their breast cancer compared to postmenopausal women who too"
-
Aromatase inhibitor letrozole guards against breast cancer relapse for up to
8 years, study finds
- Science Daily, 9/25/11
Toxicity of aromatase inhibitors may explain lack of overall survival
improvement - Science Daily, 8/22/11 - "compared
to tamoxifen, longer use of AIs was
associated with increased heart disease and bone fractures, but lower rates
of blood clots and cancer of the womb. There were no differences in the risk
of stroke or other types of cancer. Furthermore, use of AIs for 2-3 years
after initial treatment with tamoxifen was associated with a lower risk of
death unrelated to breast cancer compared to the use of either AIs or
tamoxifen alone. The authors therefore concluded that the toxicity of AIs
when used for longer periods of treatment may explain the lack of overall
survival benefit while still having a positive effect on breast cancer
recurrence"
Vitamin D relieves joint, muscle pain for breast cancer patients -
Science Daily, 7/26/11 - "Rastelli's group recruited
60 patients who reported pain and discomfort associated with anastrozole,
one of three FDA-approved aromatase inhibitors. The patients they studied
also had low vitamin D levels. Half the group was randomly assigned to
receive the recommended daily dose of vitamin D (400 international units)
plus a 50,000-unit vitamin D capsule once a week. The other half received
the daily dose of 400 units of vitamin D plus a weekly placebo. All subjects
received 1,000 milligrams of calcium daily throughout the study ... patients
receiving high-dose vitamin D every week reported significantly less
musculoskeletal pain and also were less likely to experience pain that
interfered with daily living" - See
vitamin D at Amazon.com.
Exemestane reduces breast cancer in high-risk women, researchers show -
Science Daily, 6/4/11 - "The study showed that in
postmenopausal women at increased risk of breast cancer, but who have not
previously been diagnosed with breast cancer, the aromatase inhibitor called
Aromasin, made by Pfizer, reduces this risk by 65 percent compared with
placebo" - Note: If you go the the abstract is says "Funded by Pfizer
and others" and like it says, Aromasin (exemestane) is made by Pfizer. I've
always thought of Aromasin (exemestane) as being cheaper and less effective
than Femara (letrozole) which is made by Novartis. A good study would have
included Femara.
Femara vs. Tamoxifen for Breast Cancer - WebMD, 8/19/09
Letrozole Plus FSH a
"Good Initial Option" in Older Infertile Women - Medscape, 7/8/09
Cognitive Function Better With Letrozole Than With Tamoxifen in Patients
Treated for Breast Cancer - Doctor's Guide, 6/1/09
Late
Treatment With Letrozole Can Reduce Breast Cancer Recurrence Risk -
Science daily, 3/10/08
Ki-67 Expression Appears to Identify Breast Cancer Patients That Would
Benefit From Letrozole Rather Than Tamoxifen - Doctor's Guide, 12/17/07
Vitamin D Supplementation Reduces Fatigue and Muscle Pain in Women With
Early-Stage Breast Cancer - Doctor's Guide, 12/17/07 -
"Treatment of low levels of vitamin D in women with
early stage breast cancer appears to reduce fatigue and muscle pain
associated with aromatase inhibitor therapy" - See
vitamin D at Amazon.com.
Pain Makes Some End Breast Cancer Drug - WebMD, 9/6/07 -
"23% of the women in the new study given one of two
aromatase inhibitors -- Aromasin or Femara -- stopped taking their drugs due
to side effects, which also included hot flashes and nausea ... Forty-two
percent of the women reported serious bone and joint problems, such as
severe pain or difficulty opening a jar, and were referred for evaluation by
a rheumatologist"
Hormone Help for Ovarian Cancer? - WebMD, 6/15/07 -
"The patients took a drug called Femara, which is an
aromatase inhibitor, a type of drug that curbs estrogen production ...
monitored the women's blood level of a tumor marker called CA-125, a
substance found in higher concentrations in ovarian cancer than in other
cells ... Eleven of the 42 patients (26%) showed no tumor growth over six
months, based on their CA-125 levels"
Zoledronic Acid Plus Letrozole Concurrent Treatment Prevents Bone Loss -
Doctor's Guide, 12/18/06
New 4-Year Data Confirm Letrozole Cuts Risk of Breast Cancer Recurrence and
Spread of Disease - Doctor's Guide, 10/5/06
Femara Beats Older Breast Cancer Drug - WebMD, 10/3/06
Postmenopausal Women With Breast Cancer Who Switch to Letrozole Tablets
Experience Dramatic Reduction in Risk of Recurrence, Distant Metastasis and
Improvement in Survival - Doctor's Guide, 6/15/06
Bone Loss Associated with Aromatase Inhibitor Therapy for Breast Cancer
Confirmed - Doctor's Guide, 6/4/06 -
"Aromatase inhibitor use was associated with a
relative risk (RR) ratio of 1.3"
Patients Have Longer Disease-Free Survival on Letrozole When They Have
Estrogen Receptor-Positive/Progesterone Receptor-Positive Disease -
Doctor's Guide, 3/27/06
Letrozole Reduces Recurrence More Than Tamoxifen in Early Breast Cancer
- Doctor's Guide, 3/27/06
New Clinical Data Show Benefits of Femara(R) for Women With Breast Cancer
Even After Prolonged Period of No Anti-Cancer Treatment Post-tamoxifen -
Doctor's Guide, 3/23/06
ZO-FAST Trial Shows Early Use of Zoledronic Acid Prevents Bone Loss with
Letrozole - Doctor's Guide, 3/22/06
Letrozole May Be Useful Adjuvant Therapy for Endocrine-Responsive Breast
Cancer - Medscape, 1/3/06
Femara® Receives US Approval as Initial Therapy for Postmenopausal Women
With Early Breast Cancer After Surgery - Doctor's Guide, 12/29/05
Letrozole Better Than Tamoxifen in Reducing Risk of Recurrence for Breast
Cancer Survivors, IBSCG Study Published in New England Journal of Medicine
Shows - Doctor's Guide, 12/29/05
Femara May Be Better Than Tamoxifen - WebMD, 12/28/05
No Changes in Breast Density Seen in Response to Treatment with Letrozole
(Femara) - Doctor's Guide, 12/13/05
Switch from Tamoxifen to Letrozole Results in Significant Improvements in
Hot Flushes, Quality of Life and Mood Among Breast Cancer Patients -
Doctor's Guide, 12/12/05
Letrozole-Bevacizumab Combination Safe and Effective in Women with Hormone
Receptor-Positive Metastatic Breast Cancer - Doctor's Guide, 12/9/05
Femara (Letrozole) Approved for Early Invasive Breast Cancer Post-Surgery
- Doctor's Guide, 12/8/05
Breast Cancer Drug Not for Fertility - WebMD, 11/30/05
Contraindication of Femara (Letrozole) in Premenopausal Women - Doctor's
Guide, 11/28/05
Long-term Consequences of the Aromatase Inhibitors - Medscape, 11/16/05
- "The "short-term toxicities," such as vasomotor
symptoms, venothromboemboli, and gynecologic complications, favor the use of
AIs. However, long-term bone loss, altered lipid profiles, and possible
compromise in sexual functioning appear to be adversely affected by the AIs"
Aromatase Inhibitors Have Different Cardiovascular Safety Profiles -
Doctor's Guide, 11/2/05
Femara Benefits Younger Women With Breast Cancer - WebMD, 10/17/05
Femara May Reduce Breast Cancer Recurrence - WebMD, 9/7/05
Letrozole More Effective Than Tamoxifen Against Breast Cancer Recurrence
- Medscape, 5/23/05
Primary Letrozole Therapy Compared to Letrozole Plus Oral Cyclophosphamide
in Elderly Women With Breast Cancer - Doctor's Guide, 5/18/05
Significant Reduction in Death and Recurrence Seen in Women Receiving
Letrozole for Breast Cancer - Doctor's Guide, 5/18/05
Femara Beats Tamoxifen for Breast Cancer - WebMD, 5/13/05
Breast Cancer
Drug Femara Beats Tamoxifen - WebMD, 1/27/05
Femara (Letrozole) Appears to Provide Disease Free-Survival Advantage in
Adjuvant Treatment of Early Breast Cancer - Doctor's Guide, 1/27/05
Letrozole Shows Benefits as Adjuvant Endocrine Therapy for Postmenopausal
Receptor-Positive Breast Cancer - Doctor's Guide, 1/27/04
FDA Approves Femara (Letrozole) as Post-Tamoxifen Treatment for Early Breast
Cancer - Doctor's Guide, 11/1/04
Emerging Successes of Aromatase Inhibitor Switching Trials Likely to
Influence Practice Patterns, Future Trials - Doctor's Guide, 7/29/04
Benefits of Aromatase Inhibitors Should Outweigh Physicians' Concerns About
Long-Term Toxicity Issues - Doctor's Guide, 7/29/04
Aromatase Inhibitors Still Superior Over Tamoxifen, but Questions Remain
About Estrogen Receptor Factors - Doctor's Guide, 7/27/04
New Aromatase Inhibitors Similarly Effective Despite Differences in
Oestrogen Suppression - Doctor's Guide, 6/30/04
FDA Grants Priority Review for Femara (Letrozole) for New Indication as
Post-Tamoxifen Treatment for Early Breast Cancer in Postmenopausal Women
- Doctor's Guide, 6/29/04
Femara (Letrozole) Appears to Significantly Reduce Spread of Early Breast
Cancer After Standard Tamoxifen Treatment in Post-Menopausal Women -
Doctor's Guide, 6/23/04
Femara (Letrozole) Addresses Ongoing Risk Of Recurrence, Spread And
Mortality From Early Breast Cancer, Beyond 5 Years After Surgery -
Doctor's Guide, 6/23/04
Novel Drug Treatment May Increase Girls' Height - Doctor's Guide,
6/21/04
Letrozole Increases
Survival Rate in Node-Positive Breast Cancer - Medscape, 6/10/04
Final MA-17 Data Shows Letrozole Reduces Mortality in Women With
Node-Positive Breast Cancer - Doctor's Guide, 6/9/04
Breast Cancer
Drug May Ease Endometriosis - WebMD, 2/13/04
Adjuvant Letrozole Cuts Risk of Recurrent Breast Cancer - Doctor's
Guide, 12/18/03
Femara (Letrozole) Appears to Reduce Breast Cancer Recurrence by Half -
Doctor's Guide, 12/15/03
Drug Combo Reduces Recurrence of Breast Cancer - Physician's Weekly,
12/1/03
New Breast Cancer Drug Leaves Questions - HealthDay, 10/17/03
Interim Data Show Improved Disease-Free Survival with Letrozole over Placebo
in Post-Tamoxifen Therapy Postmenopausal Breast Cancer Patients -
Doctor's Guide, 10/10/03
Breast Cancer Drug Shows Great Promise - HealthDay, 10/9/03
Femara Prevents
Breast Cancer Recurrence - WebMD, 10/9/03
Letrozole Confirmed Superior Over Tamoxifen As First-Line Therapy For
Postmenopausal Advanced Breast Cancer - Doctor's Guide, 7/11/03
Health Canada Confirms Treatment With Femera (Letrozole) For Advanced Breast
Cancer May Increase Survival - Doctor's Guide, 5/28/03
Letrozole Superior to Tamoxifen Regardless of Hormone Receptor Status -
Doctor's Guide, 12/13/02
Letrozole Offers Increased Quality-Adjusted Survival Compared To Tamoxifen
- Doctor's Guide, 12/13/02
Adding Letrozole to Docetaxel + Mitoxantrone of Little Benefit in First Line
Therapy of Advanced Breast Cancer - Doctor's Guide, 10/21/02
Letrozole Produces Better
Response than Anastrozole in Advanced Breast Cancer - Doctor's Guide,
5/22/02
Head-To-Head Worldwide
Study Of The Two Leading Aromatase Inhibitors Shows More Women Respond To
Femara (Letrozole) Than Arimidex (Anastrozole) In Advanced Breast Cancer
- Doctor's Guide, 5/21/02
Femara (Letrozole) More
Effective Than Arimidex (Anastrozole) at Inhibiting Estrogen in Advanced
Breast Cancer - Doctor's Guide, 1/31/02
Letrozole Superior Therapy For Postmenopausal Primary Untreated Breast
Cancer - Doctor's Guide, 12/17/01
Quality of Life Preserved
Among Women Taking Femara (Letrozole) as Second-line Hormonal Therapy for
Breast Cancer - Doctor's Guide, 12/14/01
Women With Elevated Serum
HER2 Levels Show Reduced Efficacy of Letrozole - Doctor's Guide,
12/12/01
Letrozole (Femara) Should
Be First-Line Hormonal Therapy Over Tamoxifen - Doctor's Guide, 12/12/01
Femara® (Letrozole)
Cost-Effective, Superior First-Line Therapy for Advanced Breast Cancer in
Postmenopausal Women - Doctor's Guide, 10/26/01
Letrozole More Effective Than Tamoxifen - Doctor's Guide, 10/2/01
Anti-Aromatase Agents
Cost-Effective For Women With Metastatic Breast Cancer - Doctor's Guide,
5/15/01
Femara (Letrozole Tablets)
Demonstrates Superiority Over Tamoxifen in Advanced Breast Cancer -
Doctor's Guide, 5/14/01
FDA Approves Femara
(Letrozole) For First-Line Treatment For Breast Cancer - Doctor's Guide,
1/11/01
FDA Committee Recommends
Femara (Letrozole) For Advanced Breast Cancer - Doctor's Guide, 12/13/00
Femara (Letrozole)
Significantly More Effective Than Tamoxifen In Treating Advanced Breast
Cancer - Doctor's Guide, 12/7/00
Femara (Letrozole) More
Effective Than Tamoxifen As First-Line Treatment For Advanced Breast Cancer
- Doctor's Guide, 11/9/00
Femara Effective In
Postmenopausal Women With Advanced Breast Cancer - Doctor's Guide,
2/5/98
New Advanced Breast Cancer
Drug Now Available - Doctor's Guide, 10/1/97
Abstracts:
|
|
